HansBiomed Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Guen Young Kim

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	3.3yrs
CEO ownership	n/a
Management average tenure	no data
Board average tenure	no data

Recent management updates

Recent updates

Is HansBiomed (KOSDAQ:042520) A Risky Investment?

Feb 29

HansBiomed Corporation (KOSDAQ:042520) Shares Fly 25% But Investors Aren't Buying For Growth

Feb 29

Are Dividend Investors Making A Mistake With HansBiomed Corporation (KOSDAQ:042520)?

Apr 10

Does HansBiomed (KOSDAQ:042520) Have A Healthy Balance Sheet?

Mar 06

HansBiomed's(KOSDAQ:042520) Share Price Is Down 63% Over The Past Three Years.

Jan 30

Are HansBiomed's (KOSDAQ:042520) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Dec 08

Declining Stock and Decent Financials: Is The Market Wrong About HansBiomed Corporation (KOSDAQ:042520)?

Nov 20

CEO

Guen Young Kim

3.3yrs

Tenure

Guen Young Kim serves as Chief Executive Officer of HansBiomed Corp. since January 2021.

HansBiomed Management

Management criteria checks 0/4

Key information

Recent management updates

No independent directors

No independent directors

Recent updates

New minor risk - Share price stability

Is HansBiomed (KOSDAQ:042520) A Risky Investment?

HansBiomed Corporation (KOSDAQ:042520) Shares Fly 25% But Investors Aren't Buying For Growth

First quarter 2024 earnings released: ₩79.00 loss per share (vs ₩374 loss in 1Q 2023)

Full year 2023 earnings released: ₩2,150 loss per share (vs ₩624 profit in FY 2022)

New minor risk - Share price stability

Second quarter 2023 earnings released: ₩964 loss per share (vs ₩341 profit in 2Q 2022)

Investor sentiment improves as stock rises 19%

First quarter 2023 earnings released: ₩374 loss per share (vs ₩138 loss in 1Q 2022)

Investor sentiment improved over the past week

Full year 2022 earnings released: EPS: ₩624 (vs ₩1,827 loss in FY 2021)

No independent directors

Third quarter 2022 earnings released: ₩54.00 loss per share (vs ₩182 loss in 3Q 2021)

HansBiomed Corporation (KOSDAQ:A042520) announces an Equity Buyback for KRW 2,000 million worth of its shares.

No independent directors

Full year 2021 earnings: EPS and revenues miss analyst expectations

Are Dividend Investors Making A Mistake With HansBiomed Corporation (KOSDAQ:042520)?

Does HansBiomed (KOSDAQ:042520) Have A Healthy Balance Sheet?

HansBiomed's(KOSDAQ:042520) Share Price Is Down 63% Over The Past Three Years.

New 90-day low: ₩11,650

Full year 2020 earnings released: ₩1,808 loss per share

Are HansBiomed's (KOSDAQ:042520) Statutory Earnings A Good Reflection Of Its Earnings Potential?

New 90-day low: ₩11,750

Declining Stock and Decent Financials: Is The Market Wrong About HansBiomed Corporation (KOSDAQ:042520)?

Market pulls back on stock over the past week

New 90-day low: ₩18,250

Market pulls back on stock over the past week

New 90-day high - ₩23,650

New 90-day low - ₩18,350

CEO

Tenure